Peter Ruf Selected Research

Immunoglobulin Fc Fragments

1/2021	GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma.
4/2013	Potential of the trifunctional bispecific antibody surek depends on dendritic cells: rationale for a new approach of tumor immunotherapy.
8/2012	Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter Ruf Research Topics

Disease

17	Neoplasms (Cancer) 10/2021 - 02/2004
7	Melanoma (Melanoma, Malignant) 01/2017 - 02/2004
3	Ascites 01/2012 - 05/2010
2	Carcinoma (Carcinomatosis) 01/2012 - 05/2010
1	Non-Muscle Invasive Bladder Neoplasms 09/2021
1	Neuroblastoma 01/2021
1	Ovarian Neoplasms (Ovarian Cancer) 12/2015
1	Disease Progression 12/2015
1	Lymphoma (Lymphomas) 05/2010
1	Breast Neoplasms (Breast Cancer) 05/2009
1	Graft vs Host Disease (Graft-Versus-Host Disease) 08/2008
1	Residual Neoplasm 08/2008

Drug/Important Bio-Agent (IBA)

7	catumaxomabIBA 10/2021 - 05/2010
7	Bispecific AntibodiesIBA 01/2017 - 09/2008
6	Epithelial Cell Adhesion MoleculeIBA 10/2021 - 08/2008
6	AntibodiesIBA 01/2021 - 02/2004
5	AntigensIBA 01/2021 - 02/2004
4	Immunoglobulin G (IgG)IBA 01/2021 - 05/2010
3	Immunoglobulin Fc FragmentsIBA 01/2021 - 08/2012
3	CytokinesIBA 01/2021 - 02/2004
3	GangliosidesIBA 11/2012 - 02/2004
2	GD2 gangliosideIBA 08/2015 - 08/2012
2	ertumaxomabIBA 05/2010 - 05/2009
1	Cytostatic AgentsIBA 09/2021
1	dinutuximabIBA 01/2021
1	Surface Antigens (Surface Antigen)IBA 01/2021
1	IpilimumabIBA 01/2017
1	Immune Checkpoint InhibitorsIBA 01/2017
1	DNA (Deoxyribonucleic Acid)IBA 12/2015
1	9-O-acetyl-GD3 gangliosideIBA 11/2012
1	Peptides (Polypeptides)IBA 08/2012
1	InterferonsIBA 08/2012
1	Immunoglobulins (Immunoglobulin)IBA 01/2012
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2012
1	Hepatitis B e AntigensIBA 05/2010
1	human ERBB2 proteinIBA 05/2009
1	Trastuzumab (Herceptin)FDA Link 05/2009
1	InterleukinsIBA 08/2008
1	Proteoglycans (Proteoglycan)IBA 02/2004
1	PerforinIBA 02/2004

Therapy/Procedure

7	Therapeutics 09/2021 - 02/2004
3	Immunotherapy 08/2015 - 08/2012
1	Intravesical Administration 09/2021
1	Intravenous Administration 08/2015
1	Aftercare (After-Treatment) 01/2012